REG - Diaceutics PLC - Awarded UK Research Institute Grant Funding of £1m

DiaceuticsAnnouncement

05/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241205:nRSE6548Oa&default-theme=true

RNS Number : 6548O  Diaceutics PLC  05 December 2024

Diaceutics awarded UK Research Institute Grant Funding of £1m

 

Belfast and London, 5 December 2024 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, is pleased to announce that the
Company has been awarded approximately £1m in grant funding from the United
Kingdom Research Institute (UKRI) Strength in Places Fund, to further
elucidate the gaps in clinical practices that need addressing so that all
appropriate patients benefit from precision medicine in Northern Ireland/UK.
An output of this grant is expected to be enhancements to Diaceutics' data
products in 2025.

 

Diaceutics' is proud to be a partner with many great Northern Ireland
institutions and companies that collectively support and enhance the Belfast
medical & technology community, which is critical for sustainable talent
development in the region.

 

The UKRI Strength in Places Fund, via its Wave 2 investment phase, will
provide £34m to fund the Future Medicines Institute based at Queens
University Belfast and its purpose will be to provide infrastructure &
expertise to Northern Ireland based companies and to act as a research
accelerator unit.

 

Ryan Keeling, Chief Executive Officer of Diaceutics, commented: "We are very
grateful to the UKRI for awarding this funding, which we will deploy to
support our R&D activities.  Initiatives such as this are very important
and will help us progress our data products, clinical data &
bioinformatics pipeline development, staff skills and apprenticeships
development ".

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFESFRLVIIS